Dr. Michael P. Mohning, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Colorado School of Medicine, Denver (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 188
Licensed in Colorado since 2011, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Colorado School of Medicine, Denver
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
CO license 50062 (first issued 2011; transferred to compact physician) -
Critical Care Medicine (Internal Medicine) Physician
CO license 50062 (first issued 2011; transferred to compact physician) -
Internal Medicine Physician
CO license TL-2774
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uch-Memorial Health System Colorado Springs, CO
- Boulder Community Health Boulder, CO
- Saint Joseph Hospital Denver, CO
- National Jewish Health Denver, CO
Medical groups
- National Jewish Health (247 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 188
- Services billed
- 371
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 95 | 66 |
| Established patient office or other outpatient visit, 40-54 minutes | 88 | 65 |
| Diagnostic exam of voice box using a flexible endoscope | 52 | 52 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ofev (nintedanib esylate) | 100 |
| Prednisone Other prescribers in Denver, CO | 53 |
| Mycophenolate Mofetil Other prescribers in Denver, CO | 43 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Denver, CO | 43 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Denver, CO | 38 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Denver, CO | 37 |
| Incruse Ellipta (umeclidinium bromide) Other prescribers in Denver, CO | 34 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Denver, CO | 29 |
| Pirfenidone | 28 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Denver, CO | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $125 in total to this clinician.
| United Therapeutics Corporation | $125 |
|---|
| Food and Beverage | $125 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $192,257 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.